Anavex Life Sciences submitted data for FDA discussions and received scientific advice from the EMA.
2 reports, 2 independent
Updated Nov 1
No new developments lately
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Anavex Life Sciences submitted data for FDA discussions and received scientific advice from the EMA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Anavex withdrew its application for marketing authorization from the EMA.1 source
Anavex Life Sciences received scientific advice from the EMA and submitted data to the FDA.1 source
Keep exploring
The entities involved
Related events
- Argenx SE announced it is listed on Nasdaq and is seeking FDA priority review and approval.
- The FDA requested additional clinical data from Unicycive Therapeutics.
- InflaRx is seeking discussions with the FDA and collaborating with Staidson BioPharmaceuticals on clinical trials.
- FDA approval supports NDA submission in Aurora.
- NRx Pharmaceuticals is seeking regulatory approval from the FDA for its drug candidates, NRX-100 and NRX-101.